Umbilical cord blood-derived haematopoietic stem cells (HSCs) are essential for many life-saving regenerative therapies. However, despite their advantages for transplantation, their clinical use is restricted because HSCs in cord blood are found only in small numbers 1 . Small molecules that enhance haematopoietic stem and progenitor cell (HSPC) expansion in culture have been identified 2,3 , but in many cases their mechanisms of action or the nature of the pathways they impinge on are poorly understood. A greater understanding of the molecular circuitry that underpins the selfrenewal of human HSCs will facilitate the development of targeted strategies that expand HSCs for regenerative therapies. Whereas transcription factor networks have been shown to influence the self-renewal and lineage decisions of human HSCs 4,5 , the posttranscriptional mechanisms that guide HSC fate have not been closely investigated. Here we show that overexpression of the RNAbinding protein Musashi-2 (MSI2) induces multiple pro-self-renewal phenotypes, including a 17-fold increase in short-term repopulating cells and a net 23-fold ex vivo expansion of long-term repopulating HSCs. By performing a global analysis of MSI2-RNA interactions, we show that MSI2 directly attenuates aryl hydrocarbon receptor (AHR) signalling through post-transcriptional downregulation of canonical AHR pathway components in cord blood HSPCs. Our study gives mechanistic insight into RNA networks controlled by RNA-binding proteins that underlie self-renewal and provides evidence that manipulating such networks ex vivo can enhance the regenerative potential of human HSCs.
LETTER RESEARCH
readout time of 6.5 weeks at non-limiting transplant doses, 100% of mice transplanted with MSI2-overexpressing STRCs were engrafted compared to only 50% of mice transplanted with control STRCs, indicating that MSI2 overexpression extended the duration of STRCmediated engraftment (Extended Data Fig. 3c ). We next explored the effect of short hairpin (sh)RNA-induced MSI2 knockdown on HSPC function. MSI2 knockdown did not alter the clonogenic potential of HSPCs but did decrease CFU replating threefold (Extended Data Fig. 4a-c) . In more primitive culture-initiating cells, MSI2 knockdown significantly decreased cell numbers over culture (Extended Data Fig. 4d , e) independent of increased death or altered cell cycling (data not shown). Upon transplantation, engrafted MSI2 knockdown GFP + cells showed no evidence of lineage skewing, but the frequency of cells was markedly reduced relative to the percentage of GFP + cells initially transplanted (Extended Data Fig. 4f-h) . Combined, our in vitro and in vivo data show that MSI2 knockdown reduces self-renewal in early progenitors and HSCs.
To characterize the earliest transcriptional changes induced by modulating MSI2 expression, we performed RNA sequencing (RNA-seq) on CD34 + MSI2-overexpressing and knockdown cells immediately after transduction ( Supplementary Tables 1 and 2 ). MSI2 overexpressioninduced transcriptional changes showed an inverse correlation with those induced by MSI2 knockdown, suggesting that overexpression and knockdown had opposite effects (Extended Data Fig. 5a ). When compared to transcriptome data from 38 human haematopoietic cell subpopulations 4 , genes that were significantly upregulated by MSI2 overexpression and downregulated upon MSI2 knockdown were exclusively enriched in those highly expressed in HSCs and other primitive CD34 + populations (Extended Data Fig. 5b ).
As MSI2 overexpression conferred an HSC gene expression program, we hypothesized that it could facilitate HSC expansion ex vivo. MSI2 overexpression induced a fourfold increase in CD34 + CD133 + phenotypic HSCs relative to control cells after 7 days of culture ( Fig. 2a ). We next performed an LDA to define functional HSC frequency before (day 3 post-transduction, D3) and after 7 days of ex vivo culture (day 10, D10; Extended Data Fig. 6a ). Mice transplanted with HSCs on D3 displayed no altered engraftment as a result of MSI2 overexpression; however, recipients of MSI2-overexpressing D10-expanded cells displayed multiple phenotypes of enhanced reconstitution relative to recipients of control cells, including a twofold increase in bone marrow GFP + levels without changes to lineage output, an increase in the proportion of GFP + cells within the human graft relative to pre-transplant D10 levels, an increase in GFP mean fluorescence intensity and enrichment of CD34 expression in GFP high cells (Fig. 2b, c and Extended Data Fig. 6b-h ). As the lentiviral construct design ensures that levels of GFP mirror those of MSI2, these findings indicate that high levels of MSI2 impart enhanced competitiveness and are conducive to in vivo HSPC activity. Importantly, D10 MSI2-overexpressing cultures contained more CD34 + CD133 + cells before transplantation than did control cultures (Extended Data Fig. 6i ) and, accordingly, the HSC frequency in D10 MSI2-overexpressing cultures was increased twofold relative to that in D3 MSI2-overexpressing cultures. By contrast, control cultures displayed a threefold decrease in HSC frequency. These results demonstrate that MSI2 overexpression ex vivo facilitated a net sixfold increase in HSC frequency relative to control cultures (Fig. 2g, h and Supplementary Tables 3, 4 ).
Secondary LDA transplants were performed to explore fully the effects of MSI2 overexpression and culturing on self-renewal and longterm HSCs (LT-HSCs). Robust engraftment with MSI2-overexpressing cells did not induce altered myelo-lymphopoiesis or leukaemic development ( Fig. 2e ). Secondary LDA measurements revealed that the percentage of GFP + cells in the bone marrow was 4.6-fold higher after transplantation of MSI2-overexpressing cells than after control transplantation, and LT-HSC frequency was 3.5-fold higher (Fig. 2d, f and Supplementary Table 5 ). The increase in LT-HSC frequency corresponds to MSI2-overexpressing GFP + HSCs having expanded in primary mice 2.4-fold over input as compared to a 1.5-fold decrease for control HSCs (Fig. 2g ). The level of in vivo expansion induced by MSI2 overexpression reflects the behaviour of uncultured HSCs, which undergo similarly controlled expansion during passage in mice 3,11,12 . Finally, when accounting for the total change in GFP + HSCs upon ex vivo culture, MSI2 overexpression induced a cumulative 23-fold expansion of secondary LT-HSCs relative to control ( Fig. 2g , h), indicating that elevated MSI2 expression provides a considerable selfrenewal advantage to functional HSCs during ex vivo culture.
To gain mechanistic insight into this process, we examined genes that were differentially expressed in MSI2-overexpressing cells and found that the gene encoding cytochrome P450 1B1 oxidase (CYP1B1), an effector of AHR signalling 13 , was among the most repressed ( Supplementary Table 1 ). Pathway analysis revealed that many predicted targets of AHR were enriched in the gene sets that were downregulated by MSI2 overexpression (Fig. 3a ) and upregulated by MSI2 knockdown (Extended Data Fig. 7a, b ). Binding of 
the nuclear receptor transcription factor AHR to the small molecule StemRegenin 1 (SR1) inhibits AHR target gene activation and leads to the expansion of human HSPCs in culture 2 . Gene set enrichment analysis (GSEA) showed that genes that were downregulated by MSI2 overexpression significantly matched those that were downregulated by SR1 in an SR1 dose-dependent manner (Fig. 3b , c), whereas MSI2 knockdown induced the opposite expression profile (Extended Data Fig. 7c, d ). We next examined the overlap between genes that were downregulated by MSI2 overexpression and AHR targets identified by chromatin-immunoprecipitation followed by sequencing (ChIP-seq) 14 . This comparison was extended to genes downregulated upon treatment with UM171, which expands HSPCs independently of AHR 3 . Direct transcriptional targets of AHR were enriched by 3.8-and 5.6-fold in the gene sets that were downregulated by MSI2 overexpression and SR1, respectively, compared to UM171; this overrepresentation was maintained for predicted AHR targets and suggests that MSI2 overexpression expands HSPCs by attenuating AHR signalling ( Fig. 3d and Extended Data Fig. 7e ). Furthermore, SR1 treatment increased the percentage of CD34 + cells eightfold in control cultures but only fourfold in MSI2-overexpressing cultures (Extended Data Fig. 8a, b ), a finding that suggests that SR1 and MSI2 overexpression act redundantly on HSPCs via the same pathway.
To elucidate further the connection between MSI2 and AHR, MSI2-overexpressing and control cultures were treated with the AHR agonist 6-formylindolo(3,2-b)carbazole (FICZ).
Treatment of MSI2-overexpressing cells with FICZ induced canonical AHR targets, showing that these cells remain competent for AHR activation (Extended Data Fig. 8c ). FICZ induced a marked reversal of the MSI2 overexpressionmediated increases in primary CFU-GEMMs and their replating capacities ( Fig. 3e, f ). Furthermore, FICZ-treated MSI2-overexpressing cultures displayed greater losses of phenotypic HSPCs compared to treated controls, which showed no change (Extended Data Fig. 8d , e). Together, these results show that agonist-induced restoration of AHR activity reduces the self-renewal-promoting effects of MSI2 overexpression and strongly supports the idea that MSI2 overexpression promotes HSPC expansion through downregulation of AHR signalling.
To identify key RNA targets that underlie MSI2 function, we analysed global MSI2 protein-RNA interactions using cross-linking immunoprecipitation followed by sequencing (CLIP-seq) 15 (Extended Data Fig. 9a, b ). Replicates were highly correlated via gene RPKMs (reads per kilobase of transcript per million mapped reads) and 5,552 protein-coding genes were bound in both replicates (Extended Data Fig. 9c and Fig. 4a, b ). Within the top 40% of reproducible clusters, MSI2 bound predominantly to the 3′ untranslated regions (3′UTRs) of mature mRNAs ( Fig. 4c ). Importantly, 9% of annotated proteincoding gene mRNAs were reproducible MSI2 targets, compared to 0.2% of long non-coding RNAs (Extended Data Fig. 9d ), suggesting that MSI2 controls the stability or translation of coding mRNAs. Motif analysis identified a consensus pentamer (U/G)UAGU resembling the known mouse Msi1-binding sequence 9,16 within binding sites in all genic regions; additionally, MSI2-binding sites were generally significantly more conserved than background and tended to occur after the stop codon ( Fig. 4d and Extended Data Fig. 9e -h). The presence of MSI2 binding sites within Msi1 targets 16 across species indicates that Musashi proteins may bind the same genes through 3′UTR-embedded motifs (Extended Data Fig. 9i ). Finally, target gene ontology analysis revealed 186 biological processes categories ( Supplementary Table 6 ), among the most significant of which were electron transport, oestrogen receptor signalling regulation and metabolism of small molecules, all processes known to be transcriptionally influenced by AHR signalling 17 .
Among the top 2% of enriched CLIP-seq targets ( Supplementary  Table 7 ) were the 3′UTRs of the genes for two AHR pathway components: heat shock protein 90 (HSP90) and CYP1B1. Each exhibited multiple MSI2-binding motifs correlating with overlapping clusters of CLIP-seq reads ( Fig. 4e and Extended Data Fig. 10a ). To investigate the ability of MSI2 to post-transcriptionally regulate these genes during HSPC expansion, we looked for instances of uncoupled transcript and protein expression. HSP90 displayed uncoupling of transcript (1.6-fold up) and protein (1.6-fold down) expression early in culture, but after 7 days showed further upregulated transcript expression (2.5-fold) and variable protein levels ( Fig. 4f and Extended Data Fig.  10b ). As AHR-HSP90 binding is essential for ligand-dependent transcriptional activity 13 , downregulation of HSP90 protein at the outset of HSPC culture would be expected to reduce latent AHR complex formation and attenuate AHR signalling ( Fig. 3a) . Indeed, CYP1B1 transcript and protein expression displayed twofold reductions early in culture, consistent with decreased AHR pathway activity; however, at day 7, CYP1B1 transcripts were upregulated 1.7-fold and uncoupled from protein expression, which was downregulated twofold ( Fig. 4g and Extended Data Fig. 10c ). To test whether MSI2 directly mediates post-transcriptional repression of these targets, the 3′UTRs of CYP1B1 and HSP90 were coupled to luciferase. MSI2 overexpression induced significant reductions in luciferase signal from both reporters, and this effect was mitigated when the core CLIP-seq-identified UAG motifs were mutated (Extended Data Fig. 10d, e ). As MSI2 overexpression-mediated post-transcriptional downregulation of the AHR pathway converged on CYP1B1 protein repression throughout culture, we explored the effects on HSPCs of inhibiting CYP1B1 independently with (E)-2,3′,4,5′-tetramethoxystilbene (TMS). During culture, TMS 
increased the frequency and total numbers of CD34 + cells by 1.5-fold and 2-fold, respectively ( Fig. 4h , i), phenocopying the effects of MSI2 overexpression. Finally, overexpression of both CYP1B1 lacking its 3′UTR and MSI2 decreased secondary CFU-GEMM replating efficiency (Extended Data Fig. 10f , g); this suggests that CYP1B1, while typically used to report AHR signalling, itself promotes HSPC differentiation. Our work identifies MSI2 as an important mediator of human HSPC self-renewal and ex vivo expansion that acts by coordinating the post-transcriptional regulation of proteins belonging to a shared self-renewal regulatory pathway (Extended Data Fig. 10h ). We envision that manipulation of the post-transcriptional circuitry controlled by RNA-binding proteins will provide a novel and powerful means by which to enhance the regenerative potential of not only human HSCs but also other stem-cell types.
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Technologies) with flow-sorted GFP + cells post transduction (500 cells per ml) or from day seven cultured transduced cells (12,000 cells per ml). Colony counts were carried out after 14 days of incubation. CFU-GEMMs can seed secondary colonies owing to their limited self-renewal potential 24 . Replating of MSI2-overexpressing and control CFU-GEMMs for secondary CFU analysis was performed by picking single CFU-GEMMs at day 14 and disassociating colonies by vortexing. Cells were spun and resuspended in fresh methocult, mixed with a blunt-ended needle and syringe, and then plated into single wells of a 24-well plate. Secondary CFU analysis for shMSI2-and shControl-expressing cells was performed by harvesting total colony growth from a single dish (as nearly equivalent numbers of CFU-GEMMs were present in each dish), resuspending cells in fresh methocult by mixing vigorously with a blunt-ended needle and syringe and then plating into replicate 35-mm tissue culture dishes. In both protocols, secondary colony counts were done following incubation for 10 days. For primary and secondary colony forming assays performed with the AHR agonist FICZ (Santa Cruz Biotechnology), 200 nM FICZ or 0.1% DMSO was added directly to H4434 methocult medium. Two-way ANOVA analysis was performed to compare secondary CFU output and FICZ treatment for MSI2-overexpressing or control conditions. Colonies were imaged with a Q-Colour3 digital camera (Olympus) mounted to an Olympus IX5 microscope with a 10× objective lens. Image-Pro Plus imaging software (Media Cybernetics) was used to acquire pictures and subsequent image processing was performed with ImageJ software (NIH). Lin − cord blood and Lin − CD34 + suspension cultures. Transduced human Lin − cord blood cells were sorted for GFP expression and seeded at a density of 10 5 cells per ml in IMDM 10% FBS supplemented with human growth factors IL-6 (10 ng ml −1 ), SCF (50 ng ml −1 ), FLT3-L (50 ng ml −1 ), and TPO (20 ng ml −1 ) as previously described 25 . To generate growth curves, every seven days cells were counted, washed, and resuspended in fresh medium with growth factors at a density of 10 5 cells per ml. Cells from suspension cultures were also used in clonogenic progenitor, cell cycle and apoptosis assays. Experiments performed on transduced Lin − CD34 + cord blood cells used serum-free conditions as described in the cord blood transduction subsection of Methods. For in vitro cord blood studies, biological (experimental) replicates were performed with three independent cord blood samples. Cell cycle and apoptosis assays. Cell cycle progression was monitored with the addition of BrdU to day 10 suspension cultures at a final concentration of 10 μM. After 3 h of incubation, cells were assayed with the BrdU Flow Kit (BD Biosciences) according to the manufacturer's protocol. Cell proliferation and quiescence were measured using Ki67 (BD Bioscience) and Hoechst 33342 (Sigma) on day 4 suspension cultures after fixing and permeabilizing cells with the Cytofix/ Cytoperm kit (BD Biosciences). For apoptosis analysis, Annexin V (Invitrogen) and 7-AAD (BD Bioscience) staining of day 7 suspension cultures was performed according to the manufacturer's protocol. Intracellular flow cytometry. Lin − cord blood cells were initially stained with anti-CD34 PE (581) and anit-CD38 APC (HB7) antibodies (BD Biosciences) then fixed with the Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions. Fixed and permeabilized cells were immunostained with anti-MSI2 rabbit monoclonal IgG antibody (EP1305Y, Abcam) and detected by Alexa-488 goat anti-rabbit IgG antibody (Invitrogen). RNA-seq data processing. CD34 + cells were transduced with an MSI2overexpression or MSI2-knockdown lentivirus along with their corresponding controls and sorted for GFP expression 3 days later. Transductions for MSI2 overexpression or knockdown were each performed on two independent cord blood samples. Total RNA from transduced cells (>1 × 10 5 ) was isolated using TRIzol LS as recommended by the manufacturer (Invitrogen), and then further purified using RNeasy columns (Qiagen). Sample quality was assessed using Bioanalyzer RNA Nano chips (Agilent). Paired-end, barcoded RNA-seq sequencing libraries were then generated using the TruSeq RNA Sample Prep Kit (v2) (Illumina) following the manufacturer's protocols starting from 1 μg total RNA. The quality of library generation was then assessed using a Bioanalyzer platform (Agilent) and Illumina MiSeq-QC run was performed or quantified by qPCR using KAPA quantification kit (KAPA Biosystems). Sequencing was performed using an Illumina HiSeq2000 using TruSeq SBS v3 chemistry at the Institute for Research in Immunology and Cancer's Genomics Platform (University of Montreal) with cluster density targeted at 750,000 clusters per mm 2 and paired-end 2 × 100-bp read lengths. For each sample, 90-95 million reads were produced and mapped to the hg19 (GRCh37) human genome assembly using CASAVA (version 1.8). Read counts generated by CASAVA were processed in EdgeR (edgeR_3.12.0, R 3.2.2) using TMM normalization, paired design, and estimation of differential expression using a generalized linear model (glmFit). The false discovery rate (FDR) was calculated from the output P values using the Benjamini-Hochberg method. The fold change of logarithm of base 2 of TMM normalized data (logFC) was used to rank the data from top upregulated to top downregulated genes and FDR (0.05) was used to define METHODS Mice. NOD/SCID Il2rg null mice (Jackson Laboratory) were bred and maintained in the Stem Cell Unit animal barrier facility at McMaster University. All procedures were approved by the Animal Research Ethics Board at McMaster University. Isolation of primitive human haematopoietic cells and flow cytometry. All patient samples were obtained with informed consent and with the approval of local human subject research ethics boards at McMaster University. Human umbilical cord blood mononuclear cells were collected by centrifugation with Ficoll-Paque Plus (GE), followed by red blood cell lysis with ammonium chloride (StemCell Technologies). Cells were then incubated with a cocktail of lineagespecific antibodies (CD2, CD3, CD11b, CD11c, CD14, CD16, CD19, CD24, CD56, CD61, CD66b, and GlyA; StemCell Technologies) for negative selection of Lin − cells using an EasySep immunomagnetic column (StemCell Technologies). Live cells were discriminated on the basis of cell size, granularity and, as needed, absence of viability dye 7-AAD (BD Biosciences) uptake. All flow cytometry analysis was performed using a BD LSR II instrument (BD Biosciences). Data acquisition was conducted using BD FACSDiva software (BD Biosciences) and analysis was performed using FlowJo software (Tree Star). HSPC sorting and qRT-PCR analysis. To quantify MSI2 expression in human HSPCs, Lin − cord blood cells were stained with the appropriate antibody combinations to resolve HSC (CD34 + CD38 − CD45RA − CD90 + ), MPP (CD34 + CD38 − CD45RA − CD90 − ), CMP (CD34 + CD38 + CD71 − ) and EP (CD34 + CD38 + CD71 + ) fractions as similarly described previously 18, 19 with all antibodies from BD Biosciences: CD45RA (HI100), CD90 (5E10), CD34 (581), CD38 (HB7) and CD71 (M-A712). Cell viability was assessed using the viability dye 7AAD (BD Biosciences). All cell subsets were isolated using a BD FACSAria II cell sorter (BD Biosciences) or a MoFlo XDP cell sorter (Beckman Coulter). HemaExplorer 20 analysis was used to confirm MSI2 expression in human HSPCs and across the hierarchy. For all qRT-PCR determinations total cellular RNA was isolated with TRIzol LS reagent according to the manufacturer's instructions (Invitrogen) and cDNA was synthesized using the qScript cDNA Synthesis Kit (Quanta Biosciences). qRT-PCR was done in triplicate with PerfeCTa qPCR SuperMix Low ROX (Quanta Biosciences) with gene-specific probes (Universal Probe Library (UPL), Roche) and primers: MSI2 UPL-26, F-GGCAGCAAGAGGATCAGG, R-CCGTAGAGATCGGCGACA; HSP90 UPL-46, F-GGGCAACACCTCTACAAGGA, R-CTTGGGTCTGGGTTTCCTC; CYP1B1 UPL-20, F-ACGTACCGGCCACTATCACT, R-CTCGAGTCTGCAC ATCAGGA; GAPDH UPL-60, F-AGCCACATCGCTCAGACAC, R-GCCCAA TACGACCAAATCC; ACTB (UPL Set Reference Gene Assays, Roche). The mRNA content of samples compared by qRT-PCR was normalized based on the amplification of GAPDH or ACTB. Lentivirus production and western blot validation. MSI2 shRNAs were designed with the Dharmacon algorithm (http://www.dharmacon.com). Predicted sequences were synthesized as complimentary oligonucleotides, annealed and cloned downstream of the H1 promoter of the modfied cppt-PGK-EGFP-IRES-PAC-WPRE lentiviral expression vector 18 . Sequences for the MSI2 targeting and control RFP targeting shRNAs were as follows: shMSI2, 5′-GAGAGATCCCACTACGAAA-3′; shRFP, 5′-GTGGGAGCGCGTGATGAAC-3′. Human MSI2 cDNA (BC001526; Open Biosystems) was subcloned into the MA bi-directional lentiviral expression vector 21 . Human CYP1B1 cDNA (BC012049; Open Biosystems) was cloned in to psMALB 22 . All lentiviruses were prepared by transient transfection of 293FT (Invitrogen) cells with pMD2.G and psPAX2 packaging plasmids (Addgene) to create VSV-G pseudotyped lentiviral particles. All viral preparations were titrated on HeLa cells before use on cord blood. Standard SDS-PAGE and western blotting procedures were performed to validate the effects of knockdown on transduced NB4 cells (DSMZ) and overexpression on 293FT cells. Immunoblotting was performed with anti-MSI2 rabbit monoclonal IgG (EP1305Y, Epitomics) and β-actin mouse monoclonal IgG (ACTBD11B7, Santa Cruz Biotechnology) antibodies. Secondary antibodies used were IRDye 680 goat anti-rabbit IgG and IRDye 800 goat anti-mouse IgG (LI-COR). 293FT and NB4 cell lines tested negative for mycoplasma. NB4 cells were authenticated by ATRA treatment before use. Cord blood transduction. Cord blood transductions were conducted as described previously 18, 23 . Briefly, thawed Lin − cord blood or flow-sorted Lin − CD34 + CD38 − or Lin − CD34 + CD38 + cells were prestimulated for 8-12 h in StemSpan medium (StemCell Technologies) supplemented with growth factors interleukin 6 (IL-6; 20 ng ml −1 , Peprotech), stem cell factor (SCF; 100 ng ml −1 , R&D Systems), Flt3 ligand (FLT3-L; 100 ng ml −1 , R&D Systems) and thrombopoietin (TPO; 20 ng ml −1 , Peprotech). Lentivirus was then added in the same medium at a multiplicity of infection of 30-100 for 24 h. Cells were then given 2 days after transduction before use in in vitro or in vivo assays. For in vitro cord blood studies biological (experimental) replicates were performed with three independent cord blood samples. Clonogenic progenitor assays. Human clonogenic progenitor cell assays were done in semi-solid methylcellulose medium (Methocult H4434; StemCell non-limiting 5 × 10 4 day zero equivalent cell doses per mouse. For HSC expansion and LDA experiments, CD34 + CD38 − cells were sorted and transduced with MSI2-overexpressing or control vectors (50,000 cells per condition) for 3 days and then analysed for gene-transfer levels (% GFP +/− ) and primitive cell marker expression (% CD34 and CD133). To ensure that equal numbers of GFP + cells were transplanted into both control and MSI2-overexpressing recipient mice, we added identically cultured GFP − cells to the MSI2 culture to match the % GFP + of the control culture (necessary owing to the differing efficiency of transduction). The adjusted MSI2-overexpressing culture was recounted and aliquoted (63,000 cells) to match the output of half of the control culture. Three day 0 equivalent GFP + cell doses (1,000, 300 and 62 cells) were then transplanted per mouse to perform the D3 primary LDA. A second aliquot of the adjusted MSI2-overexpressing culture was then taken and put into culture in parallel with the remaining half of the control culture to perform another LDA after 7 days of growth (10 days total growth, D10 primary LDA). Altogether, four cell doses were transplanted; when converted back to day 0 equivalents these equalled approximately 1,000, 250, 100, and 20 GFP + cells per mouse, respectively. Pooled bone marrow from six engrafted primary mice that received D10 cultured control or MSI2-overexpressing cells (from the two highest doses transplanted) was aliquoted into five cell doses of 15 million, 10 million, 6 million, 2 million and 1 million cells. The numbers of GFP + cells within primary mice was estimated from nucleated cell counts obtained from NSG femurs, tibias and pelvises and from Colvin et al. 29 . The actual numbers of GFP + cells used for determining numbers of GFP + HSCs and the number of mice transplanted for all LDA experiments is shown in Supplementary Tables 3-5. The cut-off for HSC engraftment was a demonstration of multilineage reconstitution that was set at bone marrow having >0.1% GFP + CD33 + and >0.1% GFP + CD19 + cells. HSC and STRC frequency was assessed using ELDA software 30 . For all mouse transplantation experiments, mice were age-(6-12 week) and sex-matched. All transplanted mice were included for analysis unless mice died from radiation sickness before the experimental endpoint. No randomization or blinding was performed for animal experiments. Approximately 3-6 mice were used per cell dose for each cord blood transduction and transplantation experiment. UV CLIP-seq library preparation. CLIP-seq was performed as previously described 15 . Briefly, 25 million NB4 cells (a transformed human cell line of haematopoietic origin) were washed in PBS and UV-cross-linked at 400 mJ cm −2 on ice. Cells were pelleted, lysed in wash buffer (PBS, 0.1% SDS, 0.5% Na-deoxycholate, 0.5% NP-40) and DNase-treated, and supernatants from lysates were collected for immunoprecipitation. MSI2 was immunoprecipitated overnight using 5 μg of anti-MSI2 antibody (EP1305Y, Abcam) and Protein A Dynabeads (Invitrogen). Beads containing immunoprecipated RNA were washed twice with wash buffer, high-salt wash buffer (5× PBS, 0.1% SDS, 0.5% Na-Deoxycholate, 0.5% NP-40), and PNK buffer (50 mM Tris-Cl pH 7.4, 10 mM MgCl 2 , 0.5% NP-40). Samples were then treated with 0.2 U MNase for 5 min at 37° with shaking to trim immunopreciptated RNA. MNase inactivation was then carried out with PNK + EGTA buffer (50 mM Tris-Cl pH 7.4, 20 mM EGTA, 0.5% NP-40). The sample was dephosphorylated using alkaline phosphatase (CIP, NEB) at 37° for 10 min followed by washing with PNK+EGTA, PNK buffer, and then 0.1 mg ml −1 BSA in nuclease-free water. 3′RNA linker ligation was performed at 16° overnight with the following adaptor: 5′P-UGGAAUUCUCGGGUGCCAAGG-puromycin. Samples were then washed with PNK buffer, radiolabelled using P32-y-ATP (Perkin Elmer), run on a 4-12% Bis-Tris gel and then transferred to a nitrocellulose membrane. The nitrocellulose membrane was developed via autoradiography and RNA-protein complexes 15-20 kDa above the molecular weight of MSI2 were extracted with proteinase K followed by RNA extraction with acid phenol-chloroform. A 5′RNA linker (5′HO-GUUCAGAGUUCUACAGUCCGACGAUC-OH) was ligated to the extracted RNA using T4 RNA ligase (Fermentas) for 2 h and the RNA was again purified using acid phenol-chloroform. Adaptor ligated RNA was re-suspended in nuclease-free water and reverse transcribed using Superscript III reverse transcriptase (Invitrogen). Twenty cycles of PCR were performed using NEB Phusion Polymerase using a 3′PCR primer that contained a unique Illumina barcode sequence. PCR products were run on an 8% TBE gel. Products ranging between 150 and 200 bp were extracted using the QIAquick gel extraction kit (Qiagen) and re-suspended in nuclease-free water. Two separate libraries were prepared and sent for single-end 50-bp Illumina sequencing at the Institute for Genomic Medicine at the University of California, San Diego. 47,098,127 reads from the first library passed quality filtering, of which 73.83% mapped uniquely to the human genome. 57,970,220 reads from the second library passed quality filtering, of which 69.53% mapped uniquely to the human genome. CLIP-data reproducibility was verified through high correlation between gene RPKMs and statistically significant overlaps in the clusters and genes within replicates. CLIP-seq data have been deposited in NCBI's GEO and are accessible through GEO Series accession number GSE69583. CLIP-seq mapping and cluster identification. Before sequence alignment of CLIP-seq reads to the human genome was performed, sequencing reads from significantly differentially expressed genes. RNA-seq data have been deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE70685. GSEA and iRegulon AHR target prediction. iRegulon 26 was used to retrieve the top 100 AHR predicted targets with a minimal occurrence count threshold of 5. The data were analysed using GSEA 27 with ranked data as input with parameters set to 2,000 gene-set permutations. GSEA and StemRegenin 1 (SR1) gene sets. The GEO dataset GSE28359, which contains Affymetrix Human Genome U133 Plus 2.0 Array gene expression data for CD34 + cells treated with SR1 at 30 nM, 100 nM, 300 nM and 1,000 nM was used to obtain lists of genes differentially expressed in the treated samples compared to the control ones (0 nM) 2 . Data were background corrected using Robust Multi-Array Average (RMA) and quantile normalized using the expresso() function of the affy Bioconductor package (affy_1.38.1, R 3.0.1). Lists of genes were created from the 150 top upregulated and downregulated genes from the SR1-treated samples at each dose compared to the non-treated samples (0 nM). The data were analysed using GSEA with ranked data as input with parameters set to 2,000 gene-set permutations. The normalized enrichment score (NES) and false discovery rate (FDR) were calculated for each comparison. Differentiation Map of Haematopoiesis (DMAP) population comparisons. The GEO data set GSE24759, which contains Affymetrix GeneChip HT-HG_U133A Early Access Array gene expression data for 38 distinct haematopoietic cell states 4 , was compared to the MSI2 overexpression and knockdown data. GSE24759 data were background corrected using Robust Multi-Array Average (RMA), quantile normalized using the expresso() function of the affy Bioconductor package (affy_1.38.1, R 3.0.1), batch corrected using the ComBat() function of the sva package (sva_3.6.0) and scaled using the standard score. Bar graphs were created by calculating for significantly differentially expressed genes the number of scaled data that were above (>0) or below (<0) the mean for each population. Percentages indicating for how long the observed value (set of up-or downregulated genes) was better represented in that population than random values were calculated from 1,000 trials. AHR ChIP-seq comparison with downregulated gene sets. A unique list of genes closest to AHR-bound regions previously identified from TCDD-treated MCF7 ChIP-seq data 14 was used to calculate the overlap with genes showing >1.5-fold downregulation in response to treatment with UM171 (35 nM) or SR1 (500 nM) relative to DMSO-treated samples 3 as well as with genes significantly downregulated in MSI2-overexpressing versus control treated samples (FDR < 0.05). The percentage of downregulated genes with AHR-bound regions was then plotted for each gene set. P values were generated with Fisher's exact test for comparisons between gene lists. oPOSSUM analysis for promoter AHR binding sites in downregulated gene sets. AHR transcription factor binding sites in downregulated gene sets were identified with oPOSSUM-3 28 . Genes showing >1.5-fold downregulation in response to treatment with UM171 (35 nM) or SR1 (500 nM) relative to DMSO-treated samples 3 were used along with significantly downregulated genes (FDR < 0.05) with EdgeRanalysed MSI2-overexpressing versus control-treated samples. The three gene lists were uploaded into oPOSSUM-3 and the AHR:ARNT transcription factor binding site profile was used with the matrix score threshold set at 80% to analyse the region 1,500 bp upstream and 1,000 bp downstream of the transcription start site. The percentage of downregulated genes with AHR-binding sites in their promoters was then plotted for each gene set. Fisher's exact test was used to identify significant overrepresentation of AHR-binding sites in gene lists relative to background. Analysis for human chimaerism. Eight-to 12-week-old male or female NSG mice were sublethally irradiated (315 cGy) one day before intrafemoral injection with transduced cells carried in IMDM 1% FBS at 25 μl per mouse. Injected mice were analysed for human haematopoietic engraftment 12-14 weeks after transplantation or at 3 and 6.5 weeks for STRC experiments. Mouse bones (femurs, tibiae and pelvis) and spleen were removed and bones were crushed with a mortar and pestle then filtered into single-cell suspensions. Bone marrow and spleen cells were blocked with mouse Fc block (BD Biosciences) and human IgG (Sigma) and then stained with fluorochrome-conjugated antibodies specific to human haematopoietic cells. For multilineage engraftment analysis, cells from mice were stained with CD45 (HI30) (Invitrogen), CD33 (P67.6), CD15 (HI98), CD14 (MϕP9), CD19 (HIB19), CD235a/GlyA (GA-R2), CD41a (HIP8) and CD34 (581) (BD Biosciences). HSC and STRC xenotransplantation. For MSI2 knockdown in HSCs, 5.0 × 10 4 and 2.5 × 10 4 sorted Lin − CD34 + CD38 − cells were used per short-hairpin transduction experiment, leading to transplantation of day zero equivalent cell doses of 10 × 10 3 and 6.25 × 10 3 , respectively, per mouse. For STRC LDA transplantation experiments, 10 5 sorted CD34 + CD38 + cells were used per control or MSI2-overexpressing transduction. After assessing levels of gene transfer, day zero equivalent GFP + cell doses were calculated to perform the LDA. Recipients with greater than 0.1% GFP + CD45 +/− cells were considered to be repopulated. For STRC experiments that read out extended engraftment at 6.5 weeks, 2 × 10 5 CD34 + CD38 + cells were used per overexpressing or control transduction to allow LETTER RESEARCH libraries were trimmed of polyA tails, adapters, and low quality ends using Cutadapt with parameters-match-read-wildcards-times 2 -e 0 -O 5-quality-cutoff ' 6 -m 18 -b TCGTATGCCGTCTTCTGCTTG -b ATCTCGTATGCCGTCTTCTGCTTG -b CGACAGGTTCAGAGTTCTACAGTCCGACGATC -b TGGAATTCTC GGGTGCCAAGG -b AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAA-b TTTTTTTTTTTTTTTTTTTTTTTTTTTTT TTTTTTTTTTTTTTTTTTTTT. Reads were then mapped against a database of repetitive elements derived from RepBase (version 18.05). Bowtie (version 1.0.0) with parameters -S -q -p 16 -e 100 -l 20 was used to align reads against an index generated from Repbase sequences 31 . Reads not mapped to Repbase sequences were aligned to the hg19 human genome (UCSC assembly) using STAR (version 2.3.0e) 32 with parameters-outSAMunmapped Within -outFilterMultimapNmax 1 -outFilterMultimapScoreRange 1. To identify clusters in the genome of significantly enriched CLIP-seq reads, reads that were PCR replicates were removed from each CLIP-seq library using a custom script of the same method as in ref. 33 ; otherwise, reads were kept at each nucleotide position when more than one read's 5′-end was mapped. Clusters were then assigned using the CLIPper software with parameters-bonferroni-superlocal-threshold- 34 . The ranked list of significant targets was calculated assuming a Poisson distribution, where the observed value is the number of reads in the cluster, and the background is the number of reads across the entire transcript and or across a window of 1000 bp ± the predicted cluster. Gene annotations for CLIP-seq. Transcriptomic regions and gene classes were defined using annotations found in gencode v17. Depending on the analysis, clusters were associated by the Gencode-annotated 5′UTR, 3′UTR, CDS or intronic regions. If a cluster overlapped multiple regions, or a single part of a transcript was annotated as multiple regions, clusters were iteratively assigned first as CDS, then 3′UTR, 5′UTR and finally as proximal (<500 bases from an exon) or distal (>500 bases from an exon) introns. Overlapping peaks were calculated using bedtools and pybedtools 35, 36 . Gene ontology analysis for CLIP-seq. Significantly enriched gene ontology (GO) terms were identified using a hypergeometric test that compared the number of genes that were MSI2 targets in each GO term to genes expressed in each GO term as the proper background. Expressed genes were identified using the control samples in SRA study SRP012062. Mapping was performed identically to CLIP-seq mapping, without peak calling and changing the STAR parameter outFilterMulti-mapNmax to 10. Counts were calculated with featureCounts 37 and RPKMs were then computed. Only genes with a mean RPKM > 1 between the two samples were used in the background expressed set. De novo motif and conservation analysis for CLIP-seq. Randomly located clusters within the same genic regions as predicted MSI2 clusters were used to calculate a background distribution for motif and conservation analyses. Motif analysis was performed using the HOMER algorithm as in ref. 34 . For evolutionary sequence conservation analysis, the mean (mammalian) phastCons score for each cluster was used. Immunofluorescence. CD34 + cells (>5 × 10 4 ) were transduced with an MSI2overexpression or control lentivirus. Three days later, GFP + cells were sorted and then put back in to StemSpan medium containing growth factors IL-6 (20 ng ml −1 ), SCF (100 ng ml −1 ), FLT3-L (100 ng ml −1 ) and TPO (20 ng ml −1 ). A minimum of 10,000 cells were used for immunostaining at culture days 3 and 7 after GFP sorting. Cells were fixed in 2% PFA for 10 min, washed with PBS and then cytospun on to glass slides. Cytospun cells were then permeabilized (PBS, 0.2% Triton X-100) for 20 min, blocked (PBS, 0.1% saponin, 10% donkey serum) for 30 min and stained with primary antibodies (CYP1B1 (EPR14972, Abcam); HSP90 (68/hsp90, BD Biosciences)) in PBS with 10% donkey serum for 1 h. Detection with secondary antibody was performed in PBS 10% donkey serum with Alexa-647 donkey anti-rabbit antibody or Alexa-647 donkey anti-mouse antibodies for 45 min. Slides were mounted with Prolong Gold Antifade containing DAPI (Invitrogen). Several images (200-1,000 cells total) were captured per slide at 20× magnification using an Operetta HCS Reader (Perkin Elmer) with epifluorescence illumination and standard filter sets. Columbus software (Perkin Elmer) was used to automate the identification of nuclei and cytoplasm boundaries in order to quantify mean cell fluorescence. Luciferase reporter gene assay. A 271-bp region of the CYP1B1 3′UTR that flanked CLIP-seq-identified MSI2-binding sites was cloned from human HEK293FT genomic DNA using the forward primer GTGACACAACTGTGTGATTAAAAGG and reverse primer TGATTTTTATTATTTTGGT AATGGTG and placed downstream of renilla luciferase in the dual-luciferase reporter vector pGL4 (Promega). A 271-bp geneblock (IDT) with 6 TAG > TCC mutations was cloned in to pGL4 using XbaI and NotI. The HSP90 3′UTR was amplified from HEK293FT genomic DNA with the forward primer TCTCTGGCTGAGGGATGACT and reverse primer TTTTAAGGCCAAGGAATTAAGTGA and cloned into pGL4. A geneblock of the HSP90 3′UTR (IDT) with 14 TAG > TCC mutations was cloned in to pGL4 using SfaAI and NotI. Co-transfection of wild-type or mutant luciferase reporter (40 ng) and control or MSI2-overexpressing lentiviral expression vector (100 ng) was performed in the NIH-3T3 cell line, which does not express MSI1 or One sample t-test, no change = 1; n = 6 mice receiving shControl and n = 8 mice receiving shMSI2-transduced cells pooled from two experiments. h, Representative flow plots and summary of multilineage engraftment with shControl and shMSI2 cells (gated on GFP + cells). Western blot source data are shown in Supplementary Fig. 1 . Data presented as mean ± s.e.m. Unpaired t-test, *P < 0.05; ***P < 0.001. IG_C_gene  IG_C_pseudogene  IG_D_gene  IG_J_gene  IG_J_pseudogene  IG_V_gene  IG_V_pseudogene  Mt_rRNA  Mt_tRNA  TR_C_gene  TR_D_gene  TR_J_gene  TR_J_pseudogene  TR_V_gene  TR_V_pseudogene  antisense  lincRNA  miRNA  misc_RNA  polymorphic_pseudogene  processed_transcript  protein_coding  pseudogene  rRNA  sense_intronic  sense_overlapping 
